Fabrice Hurbin

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

Dominick J. Angiolillo, C. Michael Gibson, Shuk Han Cheng et al. · Clinical Pharmacology & Therapeutics · 2010 · 277 citations

Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

Tabassome Simon, Deepak L. Bhatt, L. Bergougnan et al. · Clinical Pharmacology & Therapeutics · 2011 · 89 citations

Physiologically Based Pharmacokinetic Modeling for Sequential Metabolism: Effect of CYP2C19 Genetic Polymorphism on Clopidogrel and Clopidogrel Active Metabolite Pharmacokinetics

Nassim Djebli, David Fabre, Xavier Boulenc et al. · Drug Metabolism and Disposition · 2015 · 57 citations

Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite

Xavier Boulenc, Nassim Djebli, Juan Shi et al. · Drug Metabolism and Disposition · 2011 · 39 citations

Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis

Stephan Weidinger, Andrew Blauvelt, Kim Papp et al. · Journal of Allergy and Clinical Immunology · 2024 · 34 citations · Full text